Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 May 15;68(7):740-7.
doi: 10.1002/pros.20732.

Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study

Ilir Agalliu  1 , Miia Suuriniemi, Ludmila Prokunina-Olsson, Bo Johanneson, Francis S Collins, Janet L Stanford, Elaine A Ostrander
Affiliations

Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study

Ilir Agalliu et al. Prostate. .

Abstract

Background: Transcription factor 7-like 2 (TCF7L2) is a high mobility group-box containing protein that is a critical member of the Wnt/beta-catenin canonical signaling pathway. In addition to its recently recognized role in diabetes, aberrant TCF7L2 expression has been implicated in cancer through regulation of cell proliferation and apoptosis by c-MYC and cyclin D. It has been hypothesized that germline variants within the TCF7L2 gene previously associated with diabetes may affect cancer risk through the Wnt/beta-catenin signaling pathway. Specifically, the same risk allele of single nucleotide polymorphism (SNP) rs12255372 that is associated with diabetes (T allele) has recently been associated with an increased risk of breast cancer.

Methods: Here, we investigated associations between rs12255372 and prostate cancer risk among 1,457 cases and 1,351 controls from a population-based study.

Results: The variant TT genotype was not associated with overall prostate cancer risk. However, there was evidence that men homozygous for the variant T allele had an elevated relative risk of more aggressive prostate cancer, as defined by high Gleason score (OR = 1.7, 95% CI = 1.0-2.8) or regional/distant stage (OR = 1.7, 95% CI = 1.1-2.6) disease.

Conclusions: Our findings suggest that this variant in the TCF7L2 gene may be associated with risk of developing more clinically significant disease. These results need to be confirmed, but provide initial evidence that the TCF7L2 gene may alter risk of developing more aggressive prostate cancer.

PubMed Disclaimer

References

    1. American Cancer Society 2007.
    1. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337–347. - PubMed
    1. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case control analysis. J Urology. 1991;146:1305–1307. - PubMed
    1. Whittemore A, Wu A, Kolonel L, John E, Gallagher R, Howe G, West D, Teh C, Stamey T. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J of Epid. 1995;141:732–740. - PubMed
    1. Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwarz AG, Swanson M, Silverman DT, Morris-Brown L, Hoover RN, Fraumeni JF. Prostate cancer risk in US blacks and whites with a family history of cancer. Int J Cancer. 1995;60:361–364. - PubMed

Publication types

Substances